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Foscarnet inhibits human immunodeficiency virus (HIV) replication in vitro and decreases p24
antigenemia in patients with cytomegalovirus (CMV) retinitis. To evaluate the effect of foscarnet
on HIV replication, HIV RNA was quantitated in 17 patients before and during foscarnet therapy.
Fifteen patients had CMV retinitis, 1 had CMV encephalitis, and 1 had intractable zoster. A decrease
in HIV RNA was observed in 16 of 17 patients. Before the introduction of foscarnet, mean HIV
RNA was 5.82 ± 0.24 log RNAlmL and, after a median of 13 days of therapy, mean HIV RNA
was 5.30 ± 0.27 log RNAlmL (P < .001). Among patients with detectable p24 antigen at baseline,
a significant decrease was observed (P = .017). This decrease in HIV RNA demonstrates that
foscarnet is a potent antiretroviral drug.
Foscamet (sodium salt of phosphonoformic acid) is, in vitro,
a noncompetitive inhibitor of human immunodeficiency virus
(HIV) reverse transcriptase and decreases HIV replication [1,
2]. In AIDS patients treated with foscamet for cytomegalovirus
(CMV) retinitis, a decrease in p24 antigenemia was observed,
suggesting an inhibition of HIV replication in vivo [3, 4]. In
a large randomized study comparing foscamet with ganciclovir
for the treatment of CMV retinitis, the effect on retinitis was
similar, but patients treated with foscamet survived longer,
leading to speculation that foscamet's anti-HIV effect might
be of clinical importance [5]. In view of these data, we quanti-
tated HIV viremia before and during foscamet therapy to assess
the effect of foscamet on HIV load.
Patients and Methods
Study population. AIDS patients with CMV disease whose
physicians decided to use foscamet were enrolled retrospectively
and prospectively. Among patients enrolled prospectively, viremia
was measured using serum samples collected on day 0 (before
starting foscamet) and after 10 days of treatment. Patients were
enrolled retrospectively if frozen serum samples were available
between - 10 and 0 days and between 10 and 30 days after the
initiation of foscamet.
Quantitation ofHIV RNA, p24 antigen, and CD4+ cell counts.
Blood was collected without anticoagulant, centrifuged twice for
5 min at 1500 g, aliquoted, and stored at -75°C, all within 2 h.
Total RNA from 50 ILL of serum was extracted using an automated
system (Autogen 540; Autogen Instrument, Beverly, MA). RNA
purification was based on the single-step method of acid guanidi-
nium thiocyanate-phenol-chloroform extraction [6].
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Circulating HIV RNA was quantitated in relation to an extemal
standard, as previously described [7, 8]. Briefly, total RNA recov-
ered from 50 ILL of serum was reverse transcribed, and a 238-bp
sequence of a conserved region of the pol gene was amplified by
polymerase chain reaction. The intra- and interassay variations
were 11% and 25%, respectively (data not shown). To eliminate
interassay variation, samples from the same patient were assayed
in the same experiment. Viremia was expressed as logarithm of
HIV RNA copies per milliliter of serum.
CD4+ cell counts were determined by flow cytometry (Coulter
EPICS IV; Instrumente Gesellschaft, Basel, Switzerland) using
fluoresceinated DAKO-T3, DAKO-T8, and R-phycoerythrin
DAKO-CD4 (Dako, Glostrup, Denmark). p24 antigen levels were
measured in duplicate using batch testing (HIVAG-l; Abbott Lab-
oratories, Abbott Park, IL).
Results
Seventeen patients were enrolled in this study: 7 retrospec-
tivelyand 10 prospectively between January and October 1994.
Fifteen patients had CMV retinitis (4 relapsed during mainte-
nance therapy with ganciclovir), 1 had CMV encephalitis, and
1 had intractable disseminated zoster. The median CD4+ cell
count was 24/mm3 (range, 1-202), and all patients were diag-
nosed with AIDS before the introduction of foscamet. Eight
patients had been receiving antiretroviral treatment for >4
weeks at the time of CMV disease; 6 were receiving didanosine
and 2 were receiving zidovudine. For 2 patients, didanosine
was stopped the day foscamet was introduced, whereas the
others continued to receive didanosine or zidovudine at identi-
cal dosages (table 1). For the 9 remaining patients, antiretroviral
therapy was stopped for at least 10 weeks. Sixteen patients
received 9.0-13.5 g/day of foscamet, depending on body
weight; 1 patient received 6 g/day because of renal failure.
A decrease in HIV RNA was observed during foscamet
therapy in all but 1 patient (table 1). At baseline, the mean
(±SE) HIV RNA was 5.82 ± 0.24 log RNAimL. After a
median of 13 days of therapy, the mean HIV RNA level was
5.30 ± 0.27 log RNAImL. A statistically significant mean de-
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Table 1. Quantitation of human immunodeficiency virus (HIV) RNA and p24 antigen in 17 patients
before and during foscamet therapy.
Log HIV RNAlmL p24 antigen (ng/L)
Concomitant Baseline CD4+ Before After Before After
Patients antiretroviral* cells/mrrr' foscamet" foscarnet! foscarnet" foscamet!
1 No 40 5.47 4.67 52 Neg
2 ddI 79 6.58 5.67 284 188
3 No§ 19 5.97 5.89 Neg 12
4 ddI 1 3.86 3.45 7 Neg
5 No§ 45 4.00 3.64 172 72
6 ddl 6 4.61 4.35 Neg Neg
7 No 36 6.23 6.04 63 26
8 No 2 4.61 3.85 5 13
9 No 1 6.54 6.32 14 4
10 No 89 5.82 5.04 36 9
11 No 24 6.48 6.88 6 8
12 No 30 6.59 6.22 Neg Neg
13 ddI 2 6.74 6.46 5 15
14 No 79 6.80 6.32 139 13
15 AZT 4 5.66 4.17 33 11
16 AZT 202 6.40 4.87 5731 386
17 No 2 6.61 6.21 Neg Neg
NOTE. All patients had cytomegalovirus (CMV) retinitis, except patients 14 (disseminated zoster) and 15 (CMV
encephalitis). ddI, didanosine; AZT, zidovudine; neg, negative.
* In 6 patients, antiretroviral treatment with nucleoside analogues was continued during foscamet therapy.
t 0-10 days before foscamet.
t After 10 days of foscamet.
§Received ddl until start of foscamet.
JID 1995;172 (July)
crease of 0.53 ± 0.12 log RNA/mL was observed during ther-
apy (paired t test, P < .001). A decrease in HIV RNA of >0.7
log (>80%) was seen in 6 of 17 patients and a decrease of
>0.3 log (>50%) in 11 patients. One patient had an increase
in HIV RNA.
Of 13 patients who were p24 antigen-positive at baseline
(range, 5-5531 ng/L), 10 had decreased levels (range, -34%
to -100%) during therapy (table 1) that were statistically sig-
nificant (Wilcoxon paired test, P = .017). Of the 4 patients
who were p24 antigen-negative at baseline, 3 remained nega-
tive and 1 became positive.
Median survival after the diagnosis ofCMV disease or zoster
was 5 months (range, 1-13).
Discussion
Ganciclovir and foscamet are equally efficacious for the
treatment of CMV retinitis [5, 9, 10]. However, foscamet has
the potential advantage of also inhibiting HIV replication. Fos-
camet decreases p24 antigen levels [3, 4], but no data on the
impact of foscamet therapy on HIV viremia are available. Our
results show that foscamet has a measurable effect on HIV
RNA in patients with CMV disease. The decrease of HIV RNA
observed in our 17 patients is significant and comparable to
that observed with other antiretroviral drugs [7, 8, 11, 12].
Moreover, this effect was observed in patients previously
treated for several years with nucleoside analogues. In vitro
data suggest that the inhibition of HIV replication by foscamet
and zidovudine is synergistic [1, 2]. In our study, it is interest-
ing that the 2 patients receiving zidovudine during foscamet
treatment had the largest decrease in HIV viremia (- 1.49 and
-1.53 log RNA/mL).
As reported previously [3, 4], we also observed a decrease
in p24 antigen level. However, p24 antigen was not detectable
at baseline in all patients. Moreover, in 3 patients with low
p24 antigenemia (< 15 ng/L), a weak elevation in p24 antigen
level was observed, which did not correlate with the substantial
decrease seen in HIV RNA. Slight variations of p24 antigen-
emia might be the result of variations in the production of anti-
p24 antibodies over time. In this context, our results highlight
the advantages of measuring HIV RNA, which is detectable in
all patients and is a more accurate marker of HIV replication.
The median survival reported in our study was 5 months,
which is lower than that in some prospective therapeutic studies
[5]. However, we recruited patients regardless of clinical situa-
tion, associated comorbidities, or prognosis. Most of our pa-
tients had a history ofmultiple AIDS-defining events, and some
had other active opportunistic infections, thus explaining the
high mortality.
For patients with CMV retinitis, foscamet's activity against
HIV is an appealing side effect, perhaps resulting in increased
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survival [5]. Unfortunately, the drug needs to be administered
intravenously and has numerous dose-dependent adverse ef-
fects. It is unlikely, therefore, that high doses will ever be used
against HIV in patients without CMV disease or intractable
herpes. The effects on HIV of lower doses and possible synergy
with other antiretrovirals are interesting subjects for further
studies.
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